Bristol Myers Squibb (NYSE:BMY) Stock Gets Price Target Cut from Piper Sandler

Bristol Myers Squibb (NYSE:BMY) had its target price decreased by Piper Sandler from $82.00 to $78.00 in a report issued on Monday morning, Marketbeat Ratings reports. Piper Sandler currently has an overweight rating on the biopharmaceutical company’s stock.

BMY has been the topic of several other research reports. Rothschild & Co Redburn boosted their target price on shares of Bristol Myers Squibb from $51.00 to $53.00 and gave the company a “neutral” rating in a report on Thursday, October 8th. Argus upgraded Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target for the company in a report on Wednesday, August 5th. Raymond James Financial started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “strong-buy” rating for the company. Truist Financial reissued a “buy” rating and issued a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $65.50.

Bristol Myers Squibb Stock Down 1.7%

Shares of NYSE BMY opened at $60.51 on Monday. The company’s 50 day moving average price is $62.98 and its 200-day moving average price is $59.88. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. Bristol Myers Squibb has a 52-week low of $42.52 and a 52-week high of $68.64. The company has a market capitalization of $123.59 billion, a P/E ratio of 13.33, a price-to-earnings-growth ratio of 0.31 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. During the same period in the prior year, the company posted $1.46 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 5.7% compared to the same quarter last year. Equities analysts forecast that Bristol Myers Squibb will post 6.51 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.2%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb’s payout ratio is 55.51%.

Insider Buying and Selling at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.05% of the company’s stock.

Institutional Trading of Bristol Myers Squibb

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Summit Global Investments raised its position in Bristol Myers Squibb by 5.8% in the third quarter. Summit Global Investments now owns 25,044 shares of the biopharmaceutical company’s stock worth $1,563,000 after acquiring an additional 1,364 shares during the period. MGO One Seven LLC grew its position in shares of Bristol Myers Squibb by 5.1% during the 3rd quarter. MGO One Seven LLC now owns 42,221 shares of the biopharmaceutical company’s stock valued at $2,635,000 after acquiring an additional 2,037 shares during the period. Gilliland Jeter Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb during the 3rd quarter valued at $208,000. Americana Partners LLC increased its stake in shares of Bristol Myers Squibb by 19.9% in the 3rd quarter. Americana Partners LLC now owns 277,752 shares of the biopharmaceutical company’s stock worth $17,332,000 after purchasing an additional 46,008 shares in the last quarter. Finally, Aprio Wealth Management LLC increased its stake in shares of Bristol Myers Squibb by 15.5% in the 3rd quarter. Aprio Wealth Management LLC now owns 79,607 shares of the biopharmaceutical company’s stock worth $4,967,000 after purchasing an additional 10,695 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: A Bristol Myers Squibb cancer drug reportedly doubled progression-free survival in a study and also showed encouraging results in other solid tumors. The data could strengthen the company’s growth portfolio and help offset concerns about future product declines. Bristol Myers Squibb Cancer Drug Trial Article
• Positive Sentiment: One valuation analysis argues that BMY still trades below its estimated fair value and highlights the company’s cash-generation potential. That view may attract value-oriented investors following the stock’s substantial one-year advance. Bristol Myers Squibb Fair Value Analysis
• Neutral Sentiment: Bristol Myers Squibb is scheduled to report third-quarter results before the market opens Thursday. Pre-earnings coverage is focused on revenue, earnings, full-year guidance and performance from key growth products, making the report the next major catalyst for BMY. Bristol Myers Squibb Q3 2026 Earnings Preview
• Neutral Sentiment: Analyst opinions remain divided. A consolidated fair-value estimate fell from $66.71 to $65.25, while individual targets range from the $50s to the $80s, reflecting differing expectations for pipeline data, potential corporate actions and future cash flows. Bristol Myers Squibb Fair Value and Analyst Views
• Negative Sentiment: Piper Sandler cut its price target for BMY, adding pressure to the shares ahead of earnings. The target reduction suggests more cautious expectations for near-term operating performance or the company’s pipeline. Piper Sandler Price Target Cut
• Negative Sentiment: Zacks Research made small cuts to its fiscal 2027 and 2028 EPS estimates and maintains a “Hold” rating. The lower forecasts reinforce concerns that earnings may decline beyond the current year, when analysts expect approximately $6.51 per share. Bristol Myers Squibb Analyst Estimates

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.